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We	congratulate	the	IMPORT	Low1	trialists	on	another	randomised	trial	ratifying	partial	breast	irradiation	(PBI)	
and	confirming	the	original	hypothesis2,3	proposed	in	the	Lancet	20	years	ago4.	In	2010,	the	commentary5	
accompanying	the	first	results	of	the	TARGIT-A	trial6	of	single-dose	targeted	intraoperative	radiotherapy	
(TARGIT-IORT)	presented	PBI	as	the	new	standard	for	suitable	patients.	5-year	results	of	TARGIT-A7	were	
confirmed8	in	the	GEC-ESTRO	brachytherapy	trial.	The	IMPORT-Low	trial	re-confirms	randomised	external-
beam	data	from	Florence9,	widening	the	spectrum	of	therapeutic	approaches.	The	small	survival	benefit	first	
reported	in	TARGIT-A	(5-year	overall	mortality:	TARGIT	3.9%,	EBRT	5.3%)7,10,	is	interestingly	similar	(PBI	3.7%,	
WBI	5.0	%)	and	strengthens	(figure	1)	our	meta-analysis.11		
	
	
Figure	1	Meta-analysis	of	mortality	in	6	randomised	trials	of	targeted	radiotherapy		
Forest	plots	representing	meta-analysis	of	nearly	6000	patients	in	randomised	trials	of	partial	breast	
irradiation	(PBI)	showing	the	difference	in	mortality	between	partial-breast	irradiation	and	whole-breast	
irradiation	(WBI).	The	trials	included	were	the	Budapest1,	TARGIT-A2,	ELIOT3,	Florence4,	GEC-ESTRO5	and	
IMPORT-LOW6. The	median	follow-up	of	all	these	trials	was	5	to	6	years.	Data	from	only	the	initial	1222	
patients	in	the	TARGIT-A	trial,	whose	median	follow-up	was	5	years,	are	included.	Breast	cancer	(BC)	deaths	or	
total	deaths	were	not	available	for	the	Budapest	trial.		
There	was	no	significant	heterogeneity:	p=	0.546	for	breast	cancer,	p=.447	for	non-breast	cancer	(Non-	BC)	
and	p=.448	for	total	deaths,	with	Higgins	I2	values	0.0%	for	each.	Breast	cancer	mortality	was	not	significantly	
different	(p=0.925).		
Compared	with	whole	breast	radiotherapy,	targeted	radiotherapy	resulted	in	a	significant	reduction	in	non-
breast	cancer	mortality	by	1%	(p=0.015)	and	overall	mortality	by	1.1%	(p=0.044).		
Favours	targeted	radiotherapy	 Favours	whole	breast	radiotherapy	
	
	
IMPORT-Low	still	requires	3-weeks’	daily	commute	for	radiotherapy,	with	its	adverse	physical,	social	and	
environmental	impacts12.	They	report	significant	benefit	in	only	two	of	the	72	patient-reported	quality	of	life	
domains,	and	in	contrast	with	TARGIT-A	and	GEC-ESTRO,	no	reduction	in	clinician-assessed	radiotherapy	
toxicity.	Although	utilising	existing	machines,	its	greater	complexity	considerably	increases	the	demand	on	
radiotherapy	departments,	and	costs	to	the	taxpayer	-	medical	and	departmental	charges	for	IMRT	–	can	be	
much	higher.	TARGIT-IORT	is	much	more	convenient	for	patients,	less	toxic,	and	incurs	a	lower	overall	cost	to	
health	systems	such	as	the	NHS6,7,10,12-17.	Patients	clearly	recognise	these	benefits	that	enable	such	a	rapid	
return	to	normal	life:	over	20,000	have	chosen	TARGIT-IORT,	in	over	300	centres	worldwide15.		
The	oncologic	safety	of	targeted	radiotherapy	for	early	breast	cancer	is	now	well	established.	The	choice	
between	various	modalities	based	on	toxicity,	cost,	and	personal	convenience	should	rest	with	the	patient.		
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